Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: Rationale and design of a prospective, randomized, multicenter study

Journal of Nuclear Cardiology

Volumn 18, Issue 1, 2011, Pages 73-81

  Tejani, Furqan H ^a   Thompson, Randall C ^b   Iskandrian, Ami E ^c   McNutt, Bruce E ^d   Franks, Billy ^d  

^a LONG ISLAND COLLEGE HOSPITAL   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

A2A adenosine receptor agonists; caffeine; myocardial perfusion imaging; pharmacologic stress; Regadenoson

Indexed keywords

CAFFEINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARAXANTHINE; PLACEBO; REGADENOSON; THEOBROMINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; FEMALE; GATED SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; HEART RATE; HUMAN; IMAGE ANALYSIS; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; MULTICENTER STUDY; MYOCARDIAL PERFUSION IMAGING; PARALLEL DESIGN; PHARMACOLOGIC STRESS TESTING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CAFFEINE; CARDIAC-GATED SINGLE-PHOTON EMISSION COMPUTER-ASSISTED TOMOGRAPHY; CENTRAL NERVOUS SYSTEM STIMULANTS; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXERCISE TEST; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; PREVALENCE; PROSPECTIVE STUDIES; PURINES; PYRAZOLES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; UNITED STATES; YOUNG ADULT;

EID: 79951670267     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12350-010-9311-6     Document Type: Article

References (49)

1. Henzlova MJ, Cerqueira MD, Taillefer R, Mahmarian JJ, Yao SS. Stress protocols and tracers. J Nucl Cardiol 2009;16. doi: 10.1007/s12350-009-9062-4 :.
2. American Society of Nuclear Cardiology. Imaging guidelines for nuclear cardiology procedures. http://www.asnc.org/imageuploads/ ImagingGuidelinesComplete070709.pdf. Accessed March 3, 2010.
3. HW Strauss DD Miller MD Wittry MD Cerqueira EV Garcia AS Iskandrian, et al. 2008 Procedure guideline for myocardial perfusion imaging 3.3 J Nucl Med Technol 36 155 161 10.2967/jnmt.108.056465 18703619
4. C Anagnostopoulos M Harbinson A Kelion K Kundley CY Loong A Notghi, et al. 2004 Procedure guidelines for radionuclide myocardial perfusion imaging Heart 90 Suppl 1 i1 i10 10.1136/heart.90.suppl-1.i1 14676223
5. RN Patel RB Arteaga MK Mandawat JW Thornton VJ Robinson 2007 Pharmacologic stress myocardial perfusion imaging South Med J 100 1006 1014 17943047 (Pubitemid 47537885)
6. NC Gupta DJ Esterbrooks DE Hilleman SM Mohiuddin GE The 1992 SPECT Multicenter Adenosine Study Group. Comparison of adenosine and exercise thallium-201 single-photon emission computed tomography (SPECT) myocardial perfusion imaging J Am Coll Cardiol 19 248 257 1:STN:280:DyaK387itFGlsA%3D%3D 10.1016/0735-1097(92)90474-2 1732349
7. S Nishimura JJ Mahmarian TM Boyce MS Verani 1992 Equivalence between adenosine and exercise thallium-201 myocardial tomography: A multicenter, prospective, crossover trial J Am Coll Cardiol 20 265 275 1:STN:280: DyaK38zktVOgsQ%3D%3D 10.1016/0735-1097(92)90090-A 1634661
8. SK Varma DD Watson GA Beller 1989 Quantitative comparison of thallium-201 scintigraphy after exercise and dipyridamole in coronary artery disease Am J Cardiol 64 871 877 1:STN:280:DyaK3c%2FitlalsQ%3D%3D 10.1016/0002-9149(89)90834-5 2801554 (Pubitemid 19246161)
9. MA Josephson BG Brown HS Hecht J Hopkins CD Pierce RB Petersen 1982 Noninvasive detection and localization of coronary stenoses in patients: Comparison of resting dipyridamole and exercise thallium-201 myocardial perfusion imaging Am Heart J 103 1008 1018 1:STN:280:DyaL383gtlSntw%3D%3D 10.1016/0002-8703(82)90564-6 7081014 (Pubitemid 13137888)
10. RC Hendel 2008 Utilization management of cardiovascular imaging: Pre-certification and appropriateness J Am Coll Cardiol Imaging 1 241 248 (Pubitemid 351453838)
11. JW Daly I Hide CE Muller M Shamim 1991 Caffeine analogs: Structure-activity relationships at adenosine receptors Pharmacology 42 309 321 1:CAS:528:DyaK3MXlt1Kgu70%3D 10.1159/000138813 1658821
12. BB Fredholm K Battig J Holmen A Nehlig EE Zvartau 1999 Actions of caffeine in the brain with special reference to factors that contribute to its widespread use Pharmacol Rev 51 83 133 1:CAS:528:DyaK1MXitFWgurk%3D 10049999 (Pubitemid 29113867)
13. 2A adenosine receptor mediates coronary vasodilation J Pharmacol Exp Ther 284 1066 1073 1:CAS:528:DyaK1cXhs1ygs78%3D 9495868 (Pubitemid 28130836)
14. KN Klotz 2000 Adenosine receptors and their ligands Naunyn Schmiedebergs Arch Pharmacol 362 382 391 1:CAS:528:DC%2BD3cXotFCru7Y%3D 10.1007/s002100000315 11111832
15. M Böttcher J Czernin KT Sun ME Phelps HR Schelbert 1995 Effect of caffeine on myocardial blood flow at rest and during pharmacological vasodilation J Nucl Med 36 2016 2021 7472591
16. S Kubo E Tadamura H Toyoda M Mamede M Yamamuro Y Magata, et al. 2004 Effect of caffeine intake on myocardial hyperemic flow induced by adenosine triphosphate and dipyridamole J Nucl Med 45 730 738 1:CAS:528: DC%2BD2cXnsFygt7s%3D 15136619 (Pubitemid 47618549)
17. P Smits FH Corstens WR Aengevaeren FJ Wackers T Thien 1991 False-negative dipyridamole-thallium-201 myocardial imaging after caffeine infusion J Nucl Med 32 1538 1541 1:STN:280:DyaK3Mzjt1Ojsw%3D%3D 1869975
18. P Smits WR Aengevaeren FH Corstens T Thien 1989 Caffeine reduces dipyridamole-induced myocardial ischemia J Nucl Med 30 1723 1726 1:STN:280:DyaK3c%2FhtFenuw%3D%3D 2795213 (Pubitemid 19250729)
19. P Smits C Straatman E Pijpers T Thien 1991 Dose-dependent inhibition of the hemodynamic response to dipyridamole by caffeine Clin Pharmacol Ther 50 529 537 1:CAS:528:DyaK38Xjtl2mtw%3D%3D 10.1038/clpt.1991.178 1934866
20. J Salcedo MJ Kern 2009 Effects of caffeine and theophylline on coronary hyperemia induced by adenosine or dipyridamole Catheter Cardiovasc Interv 74 598 605 10.1002/ccd.22030 19496111
21. RA Aqel GJ Zoghbi JR Trimm SA Baldwin AE Iskandrian 2004 Effect of caffeine administered intravenously on intracoronary-administered adenosine-induced coronary hemodynamics in patients with coronary artery disease Am J Cardiol 93 343 346 1:CAS:528:DC%2BD2cXptFamsw%3D%3D 10.1016/j.amjcard. 2003.10.017 14759387 (Pubitemid 38167434)
22. GJ Zoghbi T Htay R Aqel L Blackmon J Heo AE Iskandrian 2006 Effect of caffeine on ischemia detection by adenosine single-photon emission computed tomography perfusion imaging J Am Coll Cardiol 47 2296 2302 1:CAS:528: DC%2BD28Xmt12gu7w%3D 10.1016/j.jacc.2005.11.088 16750699 (Pubitemid 43795068)
23. E Reyes CY Loong M Harbinson J Donovan C Anagnostopoulos SR Underwood 2008 High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine J Am Coll Cardiol 52 2008 2016 1:CAS:528: DC%2BD1cXhsVKlsL3N 10.1016/j.jacc.2008.08.052 19055993
24. ML Geleijnse A Elhendy PM Fioretti JR Roelandt 2000 Dobutamine stress myocardial perfusion imaging J Am Coll Cardiol 36 2017 2027 1:CAS:528: DC%2BD3cXptFSqt7s%3D 10.1016/S0735-1097(00)01012-3 11127435
25. L Banko SA Haq DA Rainaldi I Klem J Siegler J Fogel 2010 Incidence of caffeine in serum of patients undergoing dipyridamole myocardial perfusion stress test by an intensive versus routine caffeine history screening Am J Cardiol 105 1474 9 1:CAS:528:DC%2BC3cXlslyksbc%3D 10.1016/j.amjcard.2009.12.072 20451698
26. 2A adenosine receptor Nucleosides Nucleotides Nucleic Acids 20 343 360 1:CAS:528:DC%2BD3MXmslCrtbk%3D 10.1081/NCN-100002306 11563047 (Pubitemid 32821797)
27. 2A agonists J Pharmacol Exp Ther 298 209 218 1:CAS:528: DC%2BD3MXksFChtbk%3D 11408544 (Pubitemid 32574529)
28. Astellas Pharma US Inc. Lexiscan™ (regadenoson) injection. United States prescribing information. December 2009. http://www.astellas.us/docs/ lexiscan.pdf. Accessed March 2010.
29. C Buhr M Gossl R Erbel H Eggebrecht 2008 Regadenoson in the detection of coronary artery disease Vasc Health Risk Manag 4 337 340 18561509 (Pubitemid 351711962)
30. RC Hendel 2009 Update on myocardial perfusion imaging: Role of regadenoson Rep Med Imaging 2 13 23
31. AE Iskandrian TM Bateman L Belardinelli B Blackburn MD Cerqueira RC Hendel, et al. 2007 Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial J Nucl Cardiol 14 645 658 10.1016/j.nuclcard.2007.06.114 17826318 (Pubitemid 47355078)
32. 2A agonist regadenoson versus adenosine in myocardial perfusion imaging J Am Coll Cardiol Imaging 1 307 316 (Pubitemid 351676842)
33. CA Thompson 2008 FDA approves pharmacologic stress agent Am J Health Syst Pharm 65 890 (Pubitemid 351680033)
34. 2A receptor agonist J Cardiovasc Pharmacol 49 369 375 1:CAS:528:DC%2BD2sXmsFOisrc%3D 10.1097/FJC.0b013e318046f364 17577101 (Pubitemid 47000311)
35. O Gaemperli T Schepis P Koepfli PT Siegrist S Fleischman P Nguyen, et al. 2008 Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: A randomized, double-blind, placebo-controlled crossover trial J Am Coll Cardiol 51 328 329 10.1016/j.jacc.2007.10.014 18206744
36. GA Diamond JS Forrester M Hirsch HM Staniloff R Vas DS Berman, et al. 1980 Application of conditional probability analysis to the clinical diagnosis of coronary artery disease J Clin Invest 65 1210 1221 1:STN:280: DyaL3c7mtVChsA%3D%3D 10.1172/JCI109776 6767741 (Pubitemid 10043619)
37. LA Kroon 2007 Drug interactions with smoking Am J Health Syst Pharm 64 1917 1921 1:CAS:528:DC%2BD2sXhtFCgtL7F 10.2146/ajhp060414 17823102 (Pubitemid 47462906)
38. MA Butler M Iwasaki FP Guengerich FF Kadlubar 1989 Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines Proc Natl Acad Sci USA 86 7696 7700 1:CAS:528:DyaK3cXisVSn 10.1073/pnas.86.20.7696 2813353 (Pubitemid 19265255)
39. S Zevin NL Benowitz 1999 Drug interactions with tobacco smoking. An update Clin Pharmacokinet 36 425 438 1:CAS:528:DyaK1MXkvFeju7k%3D 10.2165/00003088-199936060-00004 10427467 (Pubitemid 29317490)
40. RR McCusker B Fuehrlein BA Goldberger MS Gold EJ Cone 2006 Caffeine content of decaffeinated coffee J Anal Toxicol 30 611 613 1:CAS:528: DC%2BD28XhtVOlsb3O 17132260 (Pubitemid 44600854)
41. RR McCusker BA Goldberger EJ Cone 2003 Caffeine content of specialty coffees J Anal Toxicol 27 520 522 1:CAS:528:DC%2BD3sXos1Gksrg%3D 14607010 (Pubitemid 37185866)
42. D Kovacs R Pivonka PG Khosla S Khosla 2008 Effect of caffeine on myocardial perfusion imaging using single photon emission computed tomography during adenosine pharmacologic stress Am J Ther 15 431 434 10.1097/MJT. 0b013e31815aec1b 18806518
43. J Blanchard SJ Sawers 1983 The absolute bioavailability of caffeine in man Eur J Clin Pharmacol 24 93 98 1:CAS:528:DyaL3sXhsFCrur8%3D 10.1007/BF00613933 6832208 (Pubitemid 13181790)
44. S Bangalore S Parkar FH Messerli 2007 "One" cup of coffee and nuclear SPECT to go J Am Coll Cardiol 49 528 10.1016/j.jacc.2006.10.044 17258101 author reply-9 (Pubitemid 46135888)
45. MD Cerqueira NJ Weissman V Dilsizian AK Jacobs S Kaul WK Laskey, et al. 2002 Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association Circulation 105 539 542 10.1161/hc0402.102975 11815441 (Pubitemid 34262671)
46. EP Ficaro BC Lee JN Kritzman JR Corbett 2007 Corridor4DM: The Michigan method for quantitative nuclear cardiology J Nucl Cardiol 14 455 465 10.1016/j.nuclcard.2007.06.006 17679053 (Pubitemid 47163566)
47. MT Landi R Sinha NP Lang FF Kadlubar 1999 Human cytochrome P4501A2 IARC Sci Publ 148 173 195 1:CAS:528:DyaK1MXltFOiur4%3D 10493258
48. DL Eaton EP Gallagher TK Bammler KL Kunze 1995 Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity Pharmacogenetics 5 259 274 1:CAS:528:DyaK28XjtV2r 10.1097/00008571-199510000-00001 8563766
49. JJ Mahmarian MD Cerqueira AE Iskandrian TM Bateman GS Thomas RC Hendel, et al. 2009 Regadenoson induces comparable left ventricular perfusion defects as adenosine: A quantitative analysis from the ADVANCE MPI 2 trial J Am Coll Cardiol Imaging 2 959 968